121 related articles for article (PubMed ID: 20711243)
1. Low-dose MTX combined with low-dose methylprednisolone as a first-line therapy for the treatment of acute GVHD: safety and feasibility.
Wang Y; Xu LP; Liu KY; Liu DH; Wang J; Chen H; Chen YH; Han W; Huang XJ
Bone Marrow Transplant; 2011 Jun; 46(6):892-8. PubMed ID: 20711243
[TBL] [Abstract][Full Text] [Related]
2. First-line therapy for chronic graft-versus-host disease that includes low-dose methotrexate is associated with a high response rate.
Wang Y; Xu LP; Liu DH; Chen H; Chen YH; Han W; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2009 Apr; 15(4):505-11. PubMed ID: 19285639
[TBL] [Abstract][Full Text] [Related]
3. Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Huang XJ; Jiang Q; Chen H; Xu L; Liu D; Chen Y; Han W; Zhang Y; Liu K; Lu D
Bone Marrow Transplant; 2005 Aug; 36(4):343-8. PubMed ID: 15968295
[TBL] [Abstract][Full Text] [Related]
4. [Comparison study on treatment of acute graft-versus-host disease with low-dose methotrexate in combination with low-dose methylprednisolone or standard-dose methylprednisolone].
Wang J; Xu LP; Liu DH; Liu KY; Chen H; Chen YH; Han W; Wang Y; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2011 Aug; 32(8):512-5. PubMed ID: 22338171
[TBL] [Abstract][Full Text] [Related]
5. Low-dose MTX for the treatment of acute and chronic graft-versus-host disease in children.
Inagaki J; Nagatoshi Y; Hatano M; Isomura N; Sakiyama M; Okamura J
Bone Marrow Transplant; 2008 Mar; 41(6):571-7. PubMed ID: 18026150
[TBL] [Abstract][Full Text] [Related]
6. Dismal response to high-dose methylprednisolone after failure to respond to standard dose in patients with acute GVHD.
Schechter T; Macartney C; Finkelstein Y; Gassas A; Husain M; Doyle J; Dupuis LL
Bone Marrow Transplant; 2010 Dec; 45(12):1749-53. PubMed ID: 20208573
[TBL] [Abstract][Full Text] [Related]
7. [Methotrexate for treatment of graft versus host disease after allogeneic hematopoietic stem cell transplantation].
Huang XJ; Jiang Q; Chen H; Xu LP; Liu DH; Chen YH; Han W; Zhang YC; Liu KY; Lu DP
Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(16):1097-101. PubMed ID: 16029565
[TBL] [Abstract][Full Text] [Related]
8. Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease.
Kumar S; Wolf RC; Chen MG; Gastineau DA; Gertz MA; Inwards DJ; Lacy MQ; Tefferi A; Litzow MR
Bone Marrow Transplant; 2002 Aug; 30(3):161-5. PubMed ID: 12189534
[TBL] [Abstract][Full Text] [Related]
9. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR
Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738
[TBL] [Abstract][Full Text] [Related]
10. Graft-versus-host-disease prophylaxis for matched unrelated donor bone marrow transplantation: comparison between cyclosporine-methotrexate and cyclosporine-methotrexate-methylprednisolone.
Leelasiri A; Greer JP; Stein RS; Goodman S; Brandt SA; Edwards JR; Wolff SN
Bone Marrow Transplant; 1995 Mar; 15(3):401-5. PubMed ID: 7599565
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of low-dose methotrexate for pediatric patients with steroid-refractory acute graft-versus-host disease after hematopoietic stem cell transplantation.
Inagaki J; Fukano R; Kodama Y; Nishimura M; Shimokawa M; Okamura J
Ann Hematol; 2014 Apr; 93(4):645-51. PubMed ID: 24146233
[TBL] [Abstract][Full Text] [Related]
12. Low-dose methotrexate as salvage therapy for refractory graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation.
de Lavallade H; Mohty M; Faucher C; Fürst S; El-Cheikh J; Blaise D
Haematologica; 2006 Oct; 91(10):1438-40. PubMed ID: 16963392
[TBL] [Abstract][Full Text] [Related]
13. [Prophylaxis with FK-506 for graft-versus-host disease after transplantation of bone marrow from unrelated donors].
Hamazaki T; Yagi K; Inoue M; Sakata N; Okamura T; Yasui M; Sasabe M; Kishimoto T; Inoue A; Kawa K
Rinsho Ketsueki; 2000 May; 41(5):430-6. PubMed ID: 10879106
[TBL] [Abstract][Full Text] [Related]
14. An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema.
Weatherhead SC; Wahie S; Reynolds NJ; Meggitt SJ
Br J Dermatol; 2007 Feb; 156(2):346-51. PubMed ID: 17223876
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
Hartung G; Stehle G; Sinn H; Wunder A; Schrenk HH; Heeger S; Kränzle M; Edler L; Frei E; Fiebig HH; Heene DL; Maier-Borst W; Queisser W
Clin Cancer Res; 1999 Apr; 5(4):753-9. PubMed ID: 10213209
[TBL] [Abstract][Full Text] [Related]
16. Methylprednisolone, cyclosporine and methotrexate for prophylaxis of acute graft-versus-host disease.
Yau JC; LeMaistre CF; Zagars GK; Williams LA; Meneghetti CM; Luke DR; Dunphy FR; Spinolo JA; Jagannath S; Spitzer G
Bone Marrow Transplant; 1990 Apr; 5(4):269-72. PubMed ID: 2337738
[TBL] [Abstract][Full Text] [Related]
17. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
Aschan J; Ringdén O
Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
[TBL] [Abstract][Full Text] [Related]
19. [Unrelated donor stem cell transplantation in children: low toxicity using a GvHD-prophylaxis regimen with CSA, MTX, metronidazole,iv-immunoglobulin and ATG].
Graf Finckenstein F; Zabelina T; Dürken M; Dahlke J; Kröger N; Krüger W; Janka-Schaub G; Erttmann R; Zander AR; Kabisch H
Klin Padiatr; 2002; 214(4):206-11. PubMed ID: 12165903
[TBL] [Abstract][Full Text] [Related]
20. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
